Efficacy and Safety of Efalizumab in the Treatment of Moderate-Severe Hydradenitis Suppurativa

Efficacy and Safety of Efalizumab in the Treatment of Moderate-Severe Hydradenitis Suppurativa


Efficacy and Safety of Efalizumab in the Treatment of Moderate-Severe Hydradenitis Suppurativa

Acronym: null
Other IDs: H12452-01B
NCT Number: NCT00134134
Sponsor Collaborators: New York University School of Medicine|Genentech, Inc.
Funding: Other|Industry


HIDRADENITIS SUPPURATIVA CLINICAL TRIAL STATUS

Recruiting Status: Completed
Recruiting Genders: Female
Recruiting Age Groups: Adult
Interventions: Drug: efalizumab
Phases: Phase 1


CLINICAL STUDY DETAILS & RESULTS

STUDY TYPES: Interventional
STUDY DESIGNS: Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment|Masking: Open Label
Results First Received: No Study Results Posted
Study Result (if available): No Results Available
Primary Completion Date: null
Outcome Measures: Reduction in number of inflammatory lesions 12 weeks post-baseline|Time to the reduction of lesions during 12 weeks of treatment|Percent of disease activity at various weeks after baseline


CLINICAL STUDIES DATES & MILESTONES

First Received: August 23, 2005
Start Date: February 2005
Completion Date: August 2006
Last Updated: September 7, 2006
last Verified: September 2006


Source: https://ClinicalTrials.gov/show/NCT00134134


Public Domain Source: ClinicalTrials.gov query for “Hidradenitis suppurativa” clinical studies (last updated January 2016).


Tags:

HSAWARENESS.ORG | Fighting for Hidradenitis suppurativa (HS), a.k.a Acne Inversa Patient and Doctor Awareness ©2017 hidradenitissuppurativaawareness.org  All Rights Reserved. Your use of this website constitutes explicit agreement to our Terms of Use and Privacy Policies. This website does not provide medical advice, diagnosis or treatment.

Translate »

Log in with your credentials

Forgot your details?